451 related articles for article (PubMed ID: 9774148)
1. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.
Spitaler M; Utz I; Hilbe W; Hofmann J; Grunicke HH
Biochem Pharmacol; 1998 Oct; 56(7):861-9. PubMed ID: 9774148
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
5. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.
Stein WD; Cardarelli C; Pastan I; Gottesman MM
Mol Pharmacol; 1994 Apr; 45(4):763-72. PubMed ID: 7910372
[TBL] [Abstract][Full Text] [Related]
6. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta.
Gill PK; Gescher A; Gant TW
Eur J Biochem; 2001 Aug; 268(15):4151-7. PubMed ID: 11488907
[TBL] [Abstract][Full Text] [Related]
7. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
[TBL] [Abstract][Full Text] [Related]
8. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
Ruth A; Stein WD; Rose E; Roninson IB
Biochemistry; 2001 Apr; 40(14):4332-9. PubMed ID: 11284689
[TBL] [Abstract][Full Text] [Related]
9. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
10. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
11. Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.
Drew L; Groome N; Warr JR; Rumsby MG
Oncol Res; 1996; 8(6):249-57. PubMed ID: 8895200
[TBL] [Abstract][Full Text] [Related]
12. Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).
Hofmann J; Utz I; Spitaler M; Hofer S; Rybczynska M; Beck WT; Herrmann DB; Grunicke H
Br J Cancer; 1997; 76(7):862-9. PubMed ID: 9328144
[TBL] [Abstract][Full Text] [Related]
13. Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha.
Cloud-Heflin BA; McMasters RA; Osborn MT; Chambers TC
Eur J Biochem; 1996 Aug; 239(3):796-804. PubMed ID: 8774728
[TBL] [Abstract][Full Text] [Related]
14. The transient increase of tight junction permeability induced by bryostatin 1 correlates with rapid downregulation of protein kinase C-alpha.
Clarke H; Ginanni N; Laughlin KV; Smith JB; Pettit GR; Mullin JM
Exp Cell Res; 2000 Nov; 261(1):239-49. PubMed ID: 11082294
[TBL] [Abstract][Full Text] [Related]
15. Modulation of protein kinase C in antitumor treatment.
Hofmann J
Rev Physiol Biochem Pharmacol; 2001; 142():1-96. PubMed ID: 11190577
[TBL] [Abstract][Full Text] [Related]
16. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
Dupuis ML; Ascione A; Palmisano L; Vella S; Cianfriglia M
BMC Pharmacol Toxicol; 2013 Sep; 14():47. PubMed ID: 24053678
[TBL] [Abstract][Full Text] [Related]
18. Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.
Souza PS; Madigan JP; Gillet JP; Kapoor K; Ambudkar SV; Maia RC; Gottesman MM; Fung KL
Exp Cell Res; 2015 Aug; 336(2):318-28. PubMed ID: 26101157
[TBL] [Abstract][Full Text] [Related]
19. Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins.
Kino K; Taguchi Y; Yamada K; Komano T; Ueda K
FEBS Lett; 1996 Dec; 399(1-2):29-32. PubMed ID: 8980113
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.
Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J
Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
